Positive Proof of Concept for NutriLeads Key Ingredient

53a38dad-9600-4b5d-b8ca-7a91174f66b9articleimage.jpg

02 Jan 2016 --- Nutrition and health start-up NutriLeads is celebrating the beginning of 2017 following the positive findings of a proof of concept study for humans in connection with the lead ingredient Immuno Modulatory Plant Polysaccharide-1(IMPP-1). 

Clinical research company analyze & realize GmbH, the partner in the clinical study, says IMPP-1  is safe, well tolerated and supports immune function in humans.

NutriLeads develops nutritional ingredients for application in health-promoting food products. Initially founded in 2012 based upon an invention originating from Unilever, NutriLeads closed a successful seed financing round with an investor syndicate comprising Thuja Capital, DSM Venturing BV, PPM Oost and Shift Invest in 2015 and is currently discussing a series A financing.

As a clinical research organization and consulting firm specialized in natural health products, analyze & realize GmbH was the selected partner to conduct the clinical study at its own study center in Berlin. In an overall project duration of one year, a&r’s R&D clinical department investigated IMPP-1 in healthy humans and proved with success the concept of the natural ingredient being supportive of immune function in humans.

NutriLeads is developing this patented ingredient for different food applications including dietary supplements, medical food and functional food to reach various target populations. 

IMPP-1 can be sustainably sourced from food crops.
 
The results of the first proof of concept study with IMPP-1 in healthy volunteers were evaluated by an international group of key opinion leaders from industry and academia. The experts concluded that the results demonstrate excellent tolerability and safety characteristics and significant and dose dependent stimulation of the immune system.
 
“The positive result in first proof of concept study in healthy volunteers provides the necessary confidence to go full speed ahead with our ambitious development program including several clinical trials to support the use of this proprietary ingredient from sustainable sources as dietary supplement and for application in specialized functional and medical food products”, says Ruud Albers, PhD, CEO of NutriLeads.
 
NutriLeads, as consortium leader, and four European partners – including a&r – have been awarded a €2 million Eurostars project called NIMF. 

The consortium will develop NutriLeads’ proprietary ingredient IMPP-1 into a new ingredient for medical food products to fight impaired immune function as a result of malnutrition (particularly common in a variety of patient groups).

RELATED ARTICLES
Homepicture

Algaia receives €4 million boost for seaweed extract production unit

22 May 2018 French biomarine company Algaia is to install a ...

Homepicture

Lonza: Positive start to 2018, driven by expanding healthcare businesses

04 May 2018 Lonza has reported a “positive” ...

Homepicture

Nexira enters strategic partnership for nutritionals, not giving up its acquisition plans

02 May 2018 Nexira, a global leader in natural and organic ...

Homepicture

Fermentalg reports on Q1 revenue as US expansion begins

20 Apr 2018 Fermentalg, a French supplier of microalgae for ...

Homepicture

CJ CheilJedang to expand L-Arginine and L-Citrulline production in Indonesia

13 Apr 2018 CJ CheilJedang is making plans to build a ...